Latest news with #OTCMKTS
Malaysian Reserve
10 hours ago
- Business
- Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
NEW YORK, June 27, 2025 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Carisma Therapeutics Inc. (NASDAQ: CARM)'s merger with OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company. If you are a Carisma shareholder, click here to learn more about your legal rights and options. Enzo Biochem, Inc. (OTCMKTS: ENZB)'s sale to Battery Ventures for $0.70 per share in cash. If you are an Enzo shareholder, click here to learn more about your rights and options. Guaranty Bancshares, Inc. (NYSE: GNTY)'s sale to Glacier Bancorp, Inc. for 1.0000 share of Glacier stock for each Guaranty share (subject to adjustment under certain circumstances). If you are a Guaranty shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@ or zhalper@ Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLCDaniel Sadeh, Halper, Esq.(212) 763-0060sadeh@
Business Wire
5 days ago
- Business
- Business Wire
Veradigm Provides 2025 Financial & Business Update
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing an update on commercial activity and estimated financial performance for the first quarter of 2025 compared to the prior year, details about its recent financing, and reaffirmation of its outlook for the 2025 fiscal year. 'The year started on a positive note by closing deals with over $30 million in annual contract value in the first quarter of 2025, a 25 percent increase over the same period in 2024.' said Tom Langan, Interim Chief Executive Officer. 'We remain focused on building upon this momentum throughout the remainder of 2025 while also working toward becoming current in our SEC financial filings, which we expect to occur in 2026.' Management currently estimates the following preliminary estimated unaudited financial results: Revenue on a GAAP basis is between $145 million and $147 million for the quarter ending March 31, 2025. Cash and equivalents of approximately $272 million as of March 31, 2025. Cash and equivalents decreased by approximately $23 million from Cash and equivalents as of December 31, 2024 of $295 million, reflecting approximately $13 million of outflows for prior acquisitions, approximately $6 million of outflows for capital expenditures, and approximately $4 million of net outflows for operating activities, including interest income, working capital, taxes, and $15 million of Transaction and other expenses (1). Debt (2) of approximately $208 million as of March 31, 2025 that consisted solely of the principal amount of the Company's 0.875% Convertible Senior Notes due 2027 (the '2019 convertible notes') and did not change from preliminary estimated Debt (2) as of December 31, 2024. We recently completed a debt financing, strengthening our liquidity. Borrowing amount: The borrowing amount is up to $100 million, $75 million of which was drawn at closing on June 18, 2025. An additional $25 million, currently undrawn, is accessible at Veradigm's option until December 18, 2026. Pricing: The loan is senior secured and will bear interest at a rate of SOFR + 750 basis points, with interest payable in cash or in kind through June 30, 2027 and interest payable in cash thereafter. No warrants or equity derivatives are attached to the borrowing. Term: The loan matures in five years and includes early termination provisions. JPMorgan Chase Bank, N.A., acted as sole lead arranger on the loan financing. For additional details concerning the loan, please refer to the Company's Form 8-K filed with the SEC on June 20, 2025. The Company expects Debt (2) as of June 30, 2025 will be $283 million, consisting of the $75 million in new borrowings described above and $208 million consisting solely of the principal amount of the Company's 2019 convertible notes. If all holders of the 2019 convertible notes execute their repurchase option for cash on July 1, 2025, the required repayment to noteholders would include an additional $20 million, for a total of $228 million payable to convertible noteholders. As of June 10, 2025, the Company had 108.6 million shares of common stock outstanding and 10.9 million unvested restricted stock units outstanding. The Company is working toward becoming current in its SEC filings, which the Company expects to occur during 2026, and plans to subsequently seek to relist its common stock. Financial Outlook Veradigm is affirming the following expectations for fiscal year 2025: Revenue on a GAAP basis is expected to be approximately flat compared to 2024, which the Company continues to estimate to be between $583 million and $588 million. Net cash (3) is expected to remain positive. Transaction and other revenue and expenses relate to certain favorable and unfavorable legal settlements, severance, investigations, internal reviews, restatement-related accounting advisory services and legal services and other charges incurred in connection with activities that are considered not reflective of our core business. Debt with respect to the 2019 convertible notes is calculated as $208 million, consisting solely of the principal amount of the 2019 convertible notes and excluding the repurchase price payable to holders of the 2019 convertible notes upon repurchase pursuant to the First Supplemental Indenture, dated February 5, 2024. If all holders of the Company's 2019 convertible notes were to execute their repurchase options for cash on July 1, 2025, the required repayment to holders of the 2019 convertible notes would include an additional $20 million, for a total of $228 million payable to repurchase the 2019 convertible notes. Calculated as Cash and equivalents less Debt, as defined in note (2) above. Investor Conference Call and Webcast As previously disclosed, Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Access ID # 13754301. A replay of the call will be available for a period of one year on the Veradigm investor relations website. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. Disclaimer and Forward-Looking Statement Information The estimated financial results contained in this press release are preliminary, and final results for the first quarter of 2024, fiscal year 2024 and the first quarter of 2025 may change. These preliminary results are based on our estimates and are subject to completion of our financial closing audit and financial statements. In addition, these preliminary results have not been audited by our independent registered public accounting firm. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company's financial guidance for the second quarter of 2025 and fiscal year 2025 and the Company's plans for becoming current in its SEC filings and seeking to relist its shares of common stock. These forward-looking statements are based on the current beliefs and expectations of the Company's management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as 'future,' 'anticipates,' 'believes,' 'estimates,' 'expects,' 'intends,' 'plans,' 'predicts,' 'will,' 'would,' 'could,' 'continue,' 'can,' 'may,' 'look forward,' 'aims,' 'hopes,' and 'seeks' and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, among others: risks relating to the Company's common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934, as amended; a further material delay in the Company's financial reporting or ability to hold an annual meeting of stockholders; an inability of the Company to timely prepare its delinquent financial statements; unanticipated factors or factors that the Company currently believes will not cause delay, including on the Company's remediation efforts and preparation of financial statements or other factors that could cause additional delay or adjustments; the possibility that ongoing remediation work or the audit of the Company's financial statements for the fiscal year ended December 31, 2023 or the fiscal year ended December 31, 2024 may identify additional errors and material weaknesses or other deficiencies in the Company's accounting practices; the likelihood that the control deficiencies identified or that may be identified in the future will result in additional material weaknesses in the Company's internal control over financial reporting; risks relating to the Company's voluntary disclosure to the SEC of certain information relating to the investigation by the Audit Committee of the Company's Board of Directors, the SEC's investigation, and the additional information the Company has continued to provide to the SEC based on discussions with the SEC; risks relating to the putative securities class action lawsuit filed against the Company, the putative stockholder derivative action filed against the Company, commercial litigation relating to the Company's representations regarding its financial statements and any other future litigation or investigation relating to the Company's internal control failures, the completed investigation, and reviews or related matters; changes in the financial condition of the markets that the Company serves; the Company's ability to hire qualified individuals to serve in senior leadership roles on a permanent basis, including a chief executive officer and a chief financial officer; risks associated with the Company's incurrence of additional debt and the terms and conditions of the Company's new financing arrangement; and other factors contained in the 'Risk Factors' section and elsewhere in the Company's filings with the SEC from time to time, including, but not limited to, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law.
Business Wire
5 days ago
- Business
- Business Wire
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
BOSTON & OSAKA, Japan--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. 'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.' 'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.' About Povetacicept Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias. About IgA Nephropathy (IgAN) IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN. About Primary Membranous Nephropathy (pMN) Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN. About RAINIER RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104. The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. About RUBY-3 RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. About Ono Pharmaceutical Co., Ltd Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at Vertex Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at and on the SEC's website at You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Ono Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
Business Wire
18-06-2025
- Business
- Business Wire
Veradigm to Release Business Update June 23 rd and Host Investor Call June 24 th
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participants also may access the conference call by dialing 877-405-1224 or 201-389-0848 and requesting Conference ID #13754301. A replay of the call will be available for a period of one year on the Veradigm investor relations website. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Yahoo
12-06-2025
- Business
- Yahoo
RadView Software Ltd. Announces Agenda for Annual General Meeting
RA'ANANA, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- RadView Software Ltd. (OTCMKTS:RDVWF) today announced that its Annual General Meeting of Shareholders will be held on July 23, 2025 at 15:00 PM (Israel time) at the offices of the Company, 4 Dolev Street, Raanana, 4366204, Israel The record date for the meeting is June 18, 2025. The agenda of the meeting is as follows: To re-elect Mr. Shai Beilis, Mr. Avi Fried, Mr. Ori Gal and Mr. Assaf Katan to the Company's Board of Directors, to serve until the next annual general meeting of shareholders and until their successors have been duly elected and qualified; To re-elect Mr. Hillik Nissani and Ms. Tamar Naor to the Company's Board of Directors as external directors, to hold office for 3 years, commencing on the date of their re-election; To set the compensation of the External Directors (comprised of Director Fees and a grant of additional options); To set the compensation of each of Mr. Ori Gal and Mr. Assaf Katan, directors of the Company; To approve and ratify the compensation of Mr. Firas Matar, the CEO of the Company. To approve the renewal of the Company's directors' and officers' liability insurance policy with a coverage of $3,000,000 and the Company's indemnification and exemption of directors and officers; To reapprove the Company's Compensation Policy; To approve an amendment to the Convertible Loan Agreements with the Company's controlling shareholder, Formula Ventures (Holdings) Ltd, and other certain lenders; To approve the Convertible Loan Agreements (2022) with the Company's controlling shareholder, Formula Ventures (Holdings) Ltd, and other certain lenders, as amended; To reapprove the Management Services Agreements with each of the Company's controlling shareholders, Formula Ventures Ltd. and Mr. Avi Fried; To appoint BDO, as the Company's Independent Auditors, for each of the fiscal years ending December 31, 2022, December 31, 2023 and December 31, 2024 and for such additional period until the next annual general meeting of shareholders; and To review the Auditor's Report and the Company's Consolidated Financial Statements for the fiscal years ended December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Proposals No. 1, 3, 4 and 11 are ordinary resolutions, which require the affirmative vote of a majority of the shares. Proposals 2, 5, 6 , 7, 8, 9 and 10 are special resolutions, which have other majority requirements, as more fully described in the proxy statement. The presentation to the shareholders of the Company's Consolidated Financial Statements for the fiscal years ended December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023 described in Proposal 12 does not involve a vote of the Company's shareholders. The Board recommends the approval of each of these proposals. The presence, in person or by proxy, of at least two shareholders holding at least 33⅓% of the voting rights, will constitute a quorum at the meeting. If within one-half of an hour from the time appointed for the meeting a quorum is not present, the Meeting will be adjourned to the same day in the next week, at the same time and place. Additional Information and Where to Find It In connection with the meeting, RadView will send to its shareholders as of the record date a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter. Copies of the resolutions to be adopted at the meeting, and the Company's Consolidated Financial Statements will be available to any shareholder entitled to vote at the meeting, at the Company's offices during regular business hours or upon written request, submitted to the Company. You can contact the Company by phone at +1(908)5267756, or by email, at Finance@ About RadView RadView helps companies perfect their web and mobile applications with the most reliable and flexible performance engineering platform available, for more than 25 years. We address the performance requirements of such applications throughout their product life-cycle, from initial design through development, deployment, and ongoing changes and upgrades. Visit or call in to access your portfolio
